Effect of Baseline Anemia on Outcomes After Left Main Coronary Revascularization

Prakriti Gaba; Patrick W. Serruys; Joseph F. Sabik; Arie Pieter Kappetein; Shmuel Chen; Marie Claude Morice; David E. Kandzari; Aaron Crowley; Roxana Mehran; Gregg W. Stone

doi:10.1016/j.jacc.2020.01.037

Effect of Baseline Anemia on Outcomes After Left Main Coronary Revascularization

Prakriti Gaba, Patrick W. Serruys, Joseph F. Sabik, Arie Pieter Kappetein, Shmuel Chen, Marie Claude Morice, David E. Kandzari, Aaron Crowley, Roxana Mehran, Gregg W. Stone

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	1493-1495
Number of pages	3
Journal	Journal of the American College of Cardiology
Volume	75
Issue number	12
DOIs	https://doi.org/10.1016/j.jacc.2020.01.037
State	Published - 31 Mar 2020

Access to Document

10.1016/j.jacc.2020.01.037

Cite this

@article{6535e0e13b604194b40ee5a00c246eb3,

title = "Effect of Baseline Anemia on Outcomes After Left Main Coronary Revascularization",

author = "Prakriti Gaba and Serruys, {Patrick W.} and Sabik, {Joseph F.} and Kappetein, {Arie Pieter} and Shmuel Chen and Morice, {Marie Claude} and Kandzari, {David E.} and Aaron Crowley and Roxana Mehran and Stone, {Gregg W.}",

note = "Funding Information: Please note: The EXCEL Trial is supported by Abbott. Dr. Serruys has served as a consultant for Abbott, Biosensors, Medtronic, Micell Technologies, SINOMED, Philips/Volcano, Xeltis, and HeartFlow. Dr. Sabik III has served as a consultant for Medtronic, Edwards, and Sorin; and has served on the Advisory Board of Medtronic Cardiac Surgery. Dr. Kappetein is an employee of Medtronic. Dr. Morice is the CEO of the Cardiovascular European Research Center. Dr. Kandzari has received consulting honoraria and research/grant support from Medtronic, Biotronik, and Boston Scientific. Dr. Mehran has received institutional grant support (funding to the institution) from AstraZeneca, Bayer, Beth Israel Deaconess, Bristol-Myers Squibb, CSL Behring, DSI, BSC, Novartis Pharmaceuticals, and OrbusNeich; has received consulting fees from Medscape, Regeneron Pharmaceuticals (no fee), Sanofi, and Abbott Laboratories (personal fees for speaking engagements); has received spousal consultant fees (paid to the institution) from Abiomed and The Medicines Company; has served on the Scientific Advisory Board of PLx Opco Inc./PLx Pharma Inc.; has served on the Advisory Board of Bristol-Myers Squibb (funding to the institution); has equity <1% in Claret Medical and Elixir Medical; has served on the Executive Committee (paid to the institution) of Janssen Pharmaceuticals; and has served as a member of the Data Safety Monitoring Board of Watermark Research Partners. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (EXCEL Clinical Trial [EXCEL]; NCT01205776) Funding Information: Please note: The EXCEL Trial is supported by Abbott. Dr. Serruys has served as a consultant for Abbott, Biosensors, Medtronic, Micell Technologies, SINOMED, Philips/Volcano, Xeltis, and HeartFlow. Dr. Sabik III has served as a consultant for Medtronic, Edwards, and Sorin; and has served on the Advisory Board of Medtronic Cardiac Surgery. Dr. Kappetein is an employee of Medtronic. Dr. Morice is the CEO of the Cardiovascular European Research Center. Dr. Kandzari has received consulting honoraria and research/grant support from Medtronic, Biotronik, and Boston Scientific. Dr. Mehran has received institutional grant support (funding to the institution) from AstraZeneca, Bayer, Beth Israel Deaconess, Bristol-Myers Squibb, CSL Behring, DSI, BSC, Novartis Pharmaceuticals, and OrbusNeich; has received consulting fees from Medscape, Regeneron Pharmaceuticals (no fee), Sanofi, and Abbott Laboratories (personal fees for speaking engagements); has received spousal consultant fees (paid to the institution) from Abiomed and The Medicines Company; has served on the Scientific Advisory Board of PLx Opco Inc./PLx Pharma Inc.; has served on the Advisory Board of Bristol-Myers Squibb (funding to the institution); has equity <1% in Claret Medical and Elixir Medical; has served on the Executive Committee (paid to the institution) of Janssen Pharmaceuticals; and has served as a member of the Data Safety Monitoring Board of Watermark Research Partners. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (EXCEL Clinical Trial [EXCEL]; NCT01205776 ) ",

year = "2020",

month = mar,

day = "31",

doi = "10.1016/j.jacc.2020.01.037",

language = "English",

volume = "75",

pages = "1493--1495",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "12",

}

TY - JOUR

T1 - Effect of Baseline Anemia on Outcomes After Left Main Coronary Revascularization

AU - Gaba, Prakriti

AU - Serruys, Patrick W.

AU - Sabik, Joseph F.

AU - Kappetein, Arie Pieter

AU - Chen, Shmuel

AU - Morice, Marie Claude

AU - Kandzari, David E.

AU - Crowley, Aaron

AU - Mehran, Roxana

AU - Stone, Gregg W.

N1 - Funding Information: Please note: The EXCEL Trial is supported by Abbott. Dr. Serruys has served as a consultant for Abbott, Biosensors, Medtronic, Micell Technologies, SINOMED, Philips/Volcano, Xeltis, and HeartFlow. Dr. Sabik III has served as a consultant for Medtronic, Edwards, and Sorin; and has served on the Advisory Board of Medtronic Cardiac Surgery. Dr. Kappetein is an employee of Medtronic. Dr. Morice is the CEO of the Cardiovascular European Research Center. Dr. Kandzari has received consulting honoraria and research/grant support from Medtronic, Biotronik, and Boston Scientific. Dr. Mehran has received institutional grant support (funding to the institution) from AstraZeneca, Bayer, Beth Israel Deaconess, Bristol-Myers Squibb, CSL Behring, DSI, BSC, Novartis Pharmaceuticals, and OrbusNeich; has received consulting fees from Medscape, Regeneron Pharmaceuticals (no fee), Sanofi, and Abbott Laboratories (personal fees for speaking engagements); has received spousal consultant fees (paid to the institution) from Abiomed and The Medicines Company; has served on the Scientific Advisory Board of PLx Opco Inc./PLx Pharma Inc.; has served on the Advisory Board of Bristol-Myers Squibb (funding to the institution); has equity <1% in Claret Medical and Elixir Medical; has served on the Executive Committee (paid to the institution) of Janssen Pharmaceuticals; and has served as a member of the Data Safety Monitoring Board of Watermark Research Partners. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (EXCEL Clinical Trial [EXCEL]; NCT01205776) Funding Information: Please note: The EXCEL Trial is supported by Abbott. Dr. Serruys has served as a consultant for Abbott, Biosensors, Medtronic, Micell Technologies, SINOMED, Philips/Volcano, Xeltis, and HeartFlow. Dr. Sabik III has served as a consultant for Medtronic, Edwards, and Sorin; and has served on the Advisory Board of Medtronic Cardiac Surgery. Dr. Kappetein is an employee of Medtronic. Dr. Morice is the CEO of the Cardiovascular European Research Center. Dr. Kandzari has received consulting honoraria and research/grant support from Medtronic, Biotronik, and Boston Scientific. Dr. Mehran has received institutional grant support (funding to the institution) from AstraZeneca, Bayer, Beth Israel Deaconess, Bristol-Myers Squibb, CSL Behring, DSI, BSC, Novartis Pharmaceuticals, and OrbusNeich; has received consulting fees from Medscape, Regeneron Pharmaceuticals (no fee), Sanofi, and Abbott Laboratories (personal fees for speaking engagements); has received spousal consultant fees (paid to the institution) from Abiomed and The Medicines Company; has served on the Scientific Advisory Board of PLx Opco Inc./PLx Pharma Inc.; has served on the Advisory Board of Bristol-Myers Squibb (funding to the institution); has equity <1% in Claret Medical and Elixir Medical; has served on the Executive Committee (paid to the institution) of Janssen Pharmaceuticals; and has served as a member of the Data Safety Monitoring Board of Watermark Research Partners. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (EXCEL Clinical Trial [EXCEL]; NCT01205776 )

PY - 2020/3/31

Y1 - 2020/3/31

UR - http://www.scopus.com/inward/record.url?scp=85081643509&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2020.01.037

DO - 10.1016/j.jacc.2020.01.037

M3 - Letter

C2 - 32216919

AN - SCOPUS:85081643509

SN - 0735-1097

VL - 75

SP - 1493

EP - 1495

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 12

ER -